ASCO20: Significant improvement in survival for patients with stage IV/recurrent NSCLC

Professor Martin Reck explaining the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung cancer.